ATP, a leader in life sciences venture capital, announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune and inflammatory disorders and other diseases, using self-replicating RNA (srRNA). The company raised $40 million in committed Series A.

Replicate Bioscience is designing and delivering srRNA immunotherapies to revolutionize the practice of medicine and improve and save lives. Replicate applies advanced srRNA technology in its work to prevent drug resistance in cancers; this is the company's proprietary synthetic immune lethality approach.